RESULTS OF SALVAGE HORMONAL-THERAPY (S-HT) AND SALVAGE CHEMOTHERAPY (S-CT) IN WOMEN FAILING ADJUVANT CHEMOTHERAPY (A-CT) AFTER MASTECTOMY FOR BREAST-CANCER

被引：0
|
作者：
BUCKNER, JC
INGLE, JN
OFALLON, JR
EVERSON, LK
CULLINAN, SA
KROOK, JE
AHMANN, DL
机构：
[1] MAYO CLIN & MAYO FDN,MAYO CLIN & N CENT CANC TREATMENT GRP,ROCHESTER,MN 55905
[2] ILLINOIS ONCOL ASSOCIATES,PEORIA,IL
[3] DULUTH CLIN,DULUTH,MN
来源：
BREAST CANCER RESEARCH AND TREATMENT | 1987年 / 10卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：123 / 123
页数：1
相关论文
共 44 条
  • [31] Breast cancer (BC) after curative chemotherapy (CT) in non-hodgkin's lymphoma (NHL): Drug resistance as the major cause of treatment failure
    Tsavaris, N
    Zorzos, C
    Kosmas, C
    Lazaris, A
    Katsorida, M
    Pangalis, G
    Davaris, P
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S196 - S196
  • [32] Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy:: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 trial
    Fermé, C
    Mounier, N
    Diviné, M
    Brice, P
    Stamatoullas, A
    Reman, O
    Voillat, L
    Jaubert, J
    Lederlin, P
    Colin, P
    Berger, F
    Salles, G
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) : 467 - 475
  • [33] An overall survival after successful salvage therapy in children with acute lymphoblastic leukemia treated with abbreviated chemotherapy: A Tokyo Children's Cancer Study Group study L92-13.
    Sugita, K
    Ikuta, K
    Hanada, R
    Kaneko, T
    Koike, K
    Sunami, K
    Komori, I
    Manabe, M
    Kikuchi, A
    Kinoshita, A
    Shibuya, A
    Fujita, H
    Takayama, J
    Sotomatsu, M
    Kato, Y
    Morimoto, K
    Okimoto, Y
    Toyoda, Y
    Manabe, A
    Tsuchida, M
    Saito, T
    Nakazawa, S
    BLOOD, 2001, 98 (11) : 223B - 224B
  • [34] COMBINATION OF CHEMOTHERAPY AND HORMONAL-THERAPY IN ADVANCED BREAST-CANCER WITH VINCRISTINE, ADRIAMYCIN, CYCLOPHOSPHAMIDE AND HIGH-DOSE MEDROXYPROGESTERONE ACETATE - PRELIMINARY-RESULTS OF A PHASE-II STUDY OF THE AIO (ARBEITSGEMEINSCHAFT-FUR-INTERNISTISCHE-ONKOLOGIE-DER-DEUTSCHEN-KREBSGESELLSCHAFT)GH
    WANDER, HE
    NAGEL, GA
    BLOSSEY, HC
    KORDILLA, F
    STAMM, S
    MATTHIESSEN, W
    WEISS, J
    ONKOLOGIE, 1982, : 8 - &
  • [35] Ovarian ablation (DA) in pre-menopausal women with early breast cancer prescribed 5 years tamoxifen (T) or T+ chemotherapy (CT)- results from the UKNCRI Adjuvant Breast Cancer (ABC) international trial of 2,144 patients
    Yarnold, JR
    Bliss, JM
    Earl, H
    George, D
    Lawrence, D
    Mortazavi, SH
    Perren, TJ
    Raina, V
    Spooner, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 11S - 11S
  • [36] High dose therapy (HDT) & autologous stem cell transplantation (ASCT) for adults with Hodgkin's disease (HD) in first relapse after chemotherapy - Conventional dose salvage therapy prior to ASCT has no effect on outcome: Results from the EBMT.
    Sweetenham, JW
    Taghipour, G
    Milligan, D
    Goldstone, AH
    BLOOD, 1996, 88 (10) : 1933 - 1933
  • [37] Outcomes of hormone-responsive (HR+) HER2 negative (HER2-) metastatic breast cancer (MBC) patients (P) according to their starting first-line (1st) treatment (T): chemotherapy (CT) or hormonal therapy (HT)
    Bighin, C.
    Poggio, F.
    Dozin, B.
    Ceppi, M.
    Bruzzi, P.
    D'Alonzo, A.
    Giraudi, S.
    Levaggi, A.
    Lambertini, M.
    Miglietta, L.
    Vaglica, M.
    Fontana, V.
    Iacono, G.
    Pronzato, P.
    Del Mastro, L.
    ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [38] Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+HER2-breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial.
    Brain, Etienne
    Viansone, Alessandro A.
    Bourbouloux, Emmanuelle
    Rigal, Olivier
    Ferrero, Jean-Marc
    Kirscher, Sylvie
    Allouache, Djelila
    D'hondt, Veronique
    Savoye, Aude Marie
    Durando, Xavier
    Duhoux, Francois P.
    Venat-Bouvet, Laurence
    Blot, Emmanuel
    Canon, Jean-Luc Re
    Rollot, Florence
    Bonnefoi, Herve R.
    Lemonnier, J.
    Lacroix-Triki, Magali
    Bonnetain, Franck
    Vernerey, Dewi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Local versus central laboratory discrepancies in the determination of triple-negative breast cancer (TNBC) status in a large phase III (CIBOMA/2004-01/GEICAM/2003-11) trial assessing adjuvant capecitabine (C) maintenance therapy after standard chemotherapy (CT) in early breast cancer (EBC) patients (pts)
    Ruiz-Borrego, M.
    Barrios, C. H.
    Lluch, A.
    Bines, J.
    Segalla, J. G. M.
    Ruiz, A.
    Torrecillas, L.
    Llombart-Cussac, A.
    Torres, R.
    Garcia Saenz, J. A.
    Lopez Garcia-Asenjo, J. A.
    Gomez, H. L.
    De la Haba, J. R.
    Reyes, S.
    Martinez, E.
    Baena, J. M.
    Perez-Michell, L.
    Rodriguez-Lescure, A.
    Anton, A.
    Martin, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] First Results From a Phase 3 Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1 to 3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score <25: SWOG S1007 (RxPONDER)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 6 - 7
12345